


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claim 1 (original):** A compound of formula I



wherein

each of  $R^0$ ,  $R^1$ ,  $R^2$ , and  $R^3$  independently is hydrogen,  $C_1$ - $C_8$ alkyl,  $C_2$ - $C_8$ alkenyl,  $C_2$ - $C_8$ alkinyl,  $C_3$ - $C_8$ cycloalkyl,  $C_3$ - $C_8$ cycloalkyl $C_1$ - $C_8$ alkyl,  $C_5$ - $C_{10}$ aryl $C_1$ - $C_8$ alkyl, hydroxy $C_1$ - $C_8$ alkyl,  $C_1$ - $C_8$ alkoxy $C_1$ - $C_8$ alkyl, amino $C_1$ - $C_8$ alkyl, halo $C_1$ - $C_8$ alkyl, unsubstituted or substituted  $C_5$ - $C_{10}$ aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy,  $C_1$ - $C_8$ alkoxy, hydroxy $C_1$ - $C_8$ alkoxy,  $C_1$ - $C_8$ alkoxy $C_1$ - $C_8$ alkoxy, halo $C_1$ - $C_8$ alkoxy, unsubstituted or substituted  $C_5$ - $C_{10}$ aryl $C_1$ - $C_8$ alkoxy, unsubstituted or substituted heterocyclloxy, or unsubstituted or substituted heterocyclyl $C_1$ - $C_8$ alkoxy, unsubstituted or substituted amino,  $C_1$ - $C_8$ alkylthio,  $C_1$ - $C_8$ alkylsulfinyl,  $C_1$ - $C_8$ alkylsulfonyl,  $C_5$ - $C_{10}$ arylsulfonyl, halogen, carboxy,  $C_1$ - $C_8$ alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; or

$R^0$  and  $R^1$ ,  $R^1$  and  $R^2$ , and/or  $R^2$  and  $R^3$  form, together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

$R^4$  is hydrogen or  $C_1$ - $C_8$ alkyl;

each of  $R^5$  and  $R^6$  independently is hydrogen,  $C_1$ - $C_8$ alkyl,  $C_1$ - $C_8$ alkoxy $C_1$ - $C_8$ alkyl, halo $C_1$ - $C_8$ alkyl,  $C_1$ - $C_8$ alkoxy, halogen, carboxy,  $C_1$ - $C_8$ alkoxycarbonyl, unsubstituted or substituted carbamoyl, cyano, or nitro; and

each of  $R^7$ ,  $R^8$ ,  $R^9$ , and  $R^{10}$  independently is  $C_1$ - $C_8$ alkyl,  $C_2$ - $C_8$ alkenyl,  $C_2$ - $C_8$ alkinyl,  $C_3$ - $C_8$ cycloalkyl,  $C_3$ - $C_8$ cycloalkyl $C_1$ - $C_8$ alkyl,  $C_5$ - $C_{10}$ aryl $C_1$ - $C_8$ alkyl, hydroxy $C_1$ - $C_8$ alkyl,  $C_1$ - $C_8$ alkoxy $C_1$ - $C_8$ alkyl, amino $C_1$ - $C_8$ alkyl, halo $C_1$ - $C_8$ alkyl, unsubstituted or substituted  $C_5$ - $C_{10}$ aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy,  $C_1$ - $C_8$ alkoxy, hydroxy $C_1$ - $C_8$ alkoxy,  $C_1$ -

C<sub>8</sub>alkoxyC<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>arylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylthio, C<sub>1</sub>-C<sub>8</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, C<sub>5</sub>-C<sub>10</sub>arylsulfonyl, halogen, carboxy, C<sub>1</sub>-C<sub>8</sub>alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; wherein R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> independently of each other can also be hydrogen;

or R<sup>7</sup> and R<sup>8</sup>, R<sup>8</sup> and R<sup>9</sup>, and/or R<sup>9</sup> and R<sup>10</sup> form together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

A is C or N;

and salts thereof.

**Claim 2 (original):** A compound of formula I according to claim 1, wherein each of R<sup>0</sup> or R<sup>2</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

R<sup>3</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, C<sub>5</sub>-C<sub>10</sub>arylsulfonyl, halogen, carboxy, substituted or unsubstituted carbamoyl, unsubstituted or substituted sulfamoyl; or

each pair of adjacent substituents R<sup>0</sup> and R<sup>1</sup>, or R<sup>1</sup> and R<sup>2</sup>, or R<sup>2</sup> and R<sup>3</sup> is -CH<sub>2</sub>-NH-CO-, -CH<sub>2</sub>-CH<sub>2</sub>-NH-CO-, -CH<sub>2</sub>-CO-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-CO-NH-, -CH<sub>2</sub>-NH-SO<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-NH-SO<sub>2</sub>-, -CH<sub>2</sub>-SO<sub>2</sub>-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>2</sub>-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>2</sub>-, -O-CH<sub>2</sub>-O-, or -O-CF<sub>2</sub>-O-, and such pairs wherein hydrogen in NH is replaced by C<sub>1</sub>-C<sub>8</sub>alkyl;

R<sup>4</sup> is hydrogen or C<sub>1</sub>-C<sub>8</sub>alkyl;

R<sup>5</sup> is hydrogen; C<sub>1</sub>-C<sub>8</sub>alkyl, halogen, haloC<sub>1</sub>-C<sub>8</sub>alkyl, cyano or nitro;

R<sup>6</sup> is hydrogen;

each of R<sup>7</sup> and R<sup>9</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano, or nitro; and

R<sup>10</sup> is C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen, carboxy, carbamoyl, or unsubstituted or substituted sulfamoyl; or

each pair of adjacent substituents R<sup>7</sup> and R<sup>8</sup>, or R<sup>8</sup> and R<sup>9</sup> or R<sup>9</sup> and R<sup>10</sup>, is -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-O-, -CH=CH-O-, -O-CH<sub>2</sub>-O-, or -O-CF<sub>2</sub>-O-;

A is C or N.

**Claim 3 (original):** A compound of formula I according to claim 1, wherein

each of R<sup>0</sup> or R<sup>2</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, or halogen;

R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen;

R<sup>3</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, C<sub>5</sub>-C<sub>10</sub>arylsulfonyl, halogen, carboxy, substituted or unsubstituted carbamoyl, or unsubstituted or substituted sulfamoyl; or

each pair of adjacent substituents  $R^0$  and  $R^1$ , or  $R^1$  and  $R^2$ , or  $R^2$  and  $R^3$  is  $-\text{CH}_2\text{-NH-CO}-$ ,  $-\text{CH}_2\text{-NH-SO}_2-$ ,  $-\text{CH}_2\text{-CH}_2\text{-SO}_2-$ ,  $-\text{O-CH}_2\text{-O}-$ , or  $-\text{O-CF}_2\text{-O}-$ , and such pairs wherein hydrogen in NH is replaced by  $\text{C}_1\text{-C}_8\text{alkyl}$ ;

$R^4$  is hydrogen;

$R^5$  is hydrogen, halogen,  $\text{haloC}_1\text{-C}_8\text{alkyl}$ , or nitro;

$R^6$  is hydrogen;

each of  $R^7$  and  $R^9$  independently is hydrogen,  $\text{C}_1\text{-C}_8\text{alkyl}$ ,  $\text{haloC}_1\text{-C}_8\text{alkyl}$ , unsubstituted or substituted  $\text{C}_5\text{-C}_{10}\text{aryl}$ , unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S,  $\text{C}_1\text{-C}_8\text{alkoxy}$ , unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl $\text{C}_1\text{-C}_8\text{alkoxy}$ , unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

$R^8$  is hydrogen,  $\text{C}_1\text{-C}_8\text{alkyl}$ ,  $\text{haloC}_1\text{-C}_8\text{alkyl}$ ,  $\text{C}_5\text{-C}_{10}\text{aryl}$ , unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S,  $\text{C}_1\text{-C}_8\text{alkoxy}$ ,  $\text{haloC}_1\text{-C}_8\text{alkoxy}$ ,  $\text{C}_5\text{-C}_{10}\text{aryloxy}$ , unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl $\text{C}_1\text{-C}_8\text{alkoxy}$ , unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and

$R^{10}$  is  $\text{C}_1\text{-C}_8\text{alkyl}$ ,  $\text{haloC}_1\text{-C}_8\text{alkyl}$ ,  $\text{C}_1\text{-C}_8\text{alkoxy}$ , unsubstituted or substituted heterocyclyl $\text{C}_1\text{-C}_8\text{alkoxy}$ , unsubstituted or substituted amino, or halogen; or

each pair of adjacent substituents  $R^7$  and  $R^8$ , or  $R^8$  and  $R^9$  or  $R^9$  and  $R^{10}$ , is  $-\text{NH-CH=CH}-$ ,  $-\text{CH=CH-NH}-$ ,  $-\text{NH-N=CH}-$ ,  $-\text{CH=N-NH}-$ ,  $-\text{CH}_2\text{-CH}_2\text{-CH}_2-$ ,  $-\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_2-$ ,  $-\text{O-CH}_2\text{-O}-$ , or  $-\text{O-CF}_2\text{-O}-$ ;

A is C or N.

**Claim 4 (original):** A compound of formula I according to claim 1, wherein each of  $R^0$  or  $R^2$  independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy;

$R^1$  is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;

$R^3$  is sulfamoyl, methylsulfamoyl or propylsulfamoyl; or

the pair of adjacent substituents  $R^0$  and  $R^1$ , or  $R^1$  and  $R^2$  is  $-\text{O-CH}_2\text{-O}-$ , or the pair of adjacent substituents  $R^2$  and  $R^3$  is  $-\text{CH}_2\text{-NH-CO}-$  or  $-\text{CH}_2\text{-NH-SO}_2-$ ;

$R^4$  is hydrogen;

$R^5$  is hydrogen, chloro, bromo, trifluoromethyl or nitro;

$R^6$  is hydrogen;

each of R<sup>7</sup> and R<sup>9</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and

R<sup>10</sup> is C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, or halogen; or

each pair of adjacent substituents R<sup>7</sup> and R<sup>8</sup>, or R<sup>8</sup> and R<sup>9</sup> or R<sup>9</sup> and R<sup>10</sup>, is -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-O-, or -O-CF<sub>2</sub>-O-;

A is C or N.

**Claim 5 (original):** A compound of formula I according to claim 1, wherein each of R<sup>0</sup> or R<sup>2</sup> independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy;

R<sup>1</sup> is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;

R<sup>3</sup> is sulfamoyl, methylsulfamoyl or propylsulfamoyl; or

the pair of adjacent substituents R<sup>0</sup> and R<sup>1</sup>, or R<sup>1</sup> and R<sup>2</sup> is -O-CH<sub>2</sub>-O-, or the pair of adjacent substituents R<sup>2</sup> and R<sup>3</sup> is -CH<sub>2</sub>-NH-CO- or -CH<sub>2</sub>-NH-SO<sub>2</sub>-;

R<sup>4</sup> is hydrogen;

R<sup>5</sup> is hydrogen, chloro, bromo, trifluoromethyl or nitro;

R<sup>6</sup> is hydrogen;

each of R<sup>7</sup> and R<sup>9</sup> independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;

R<sup>8</sup> is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-

morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and  
 $R^{10}$  is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or  
the pair of adjacent substituents  $R^7$  and  $R^8$  or  $R^8$  and  $R^9$  is -O-CH<sub>2</sub>-O- or the pair of adjacent substituents  $R^9$  and  $R^{10}$  is -NH-CH=CH-, -CH=N-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>- or -O-CF<sub>2</sub>-O-;  
A is C or N.


**Claim 6** (original): A compound of formula I according to claim 1, wherein  
each of  $R^0$ ,  $R^1$  or  $R^2$  is hydrogen;  
 $R^3$  is sulfamoyl, methylsulfamoyl or propylsulfamoyl;  
 $R^4$  is hydrogen;  
 $R^5$  is chloro or bromo;  
 $R^6$  is hydrogen;  
each of  $R^7$  and  $R^9$  independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbonyl;  
 $R^8$  is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and  
 $R^{10}$  is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or  
the pair of adjacent substituents  $R^7$  and  $R^8$  or  $R^8$  and  $R^9$  is -O-CH<sub>2</sub>-O-, or the pair of adjacent substituents  $R^9$  and  $R^{10}$  is -NH-CH=CH-, -CH=N-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>- or -O-CF<sub>2</sub>-O-;  
A is C or N.

**Claim 7** (original): The compound of formula I according to claim 1, wherein each of  $R^0$ ,  $R^1$  or  $R^2$  is hydrogen,  $R^3$  is methylsulfamoyl,  $R^4$  is hydrogen,  $R^5$  is bromo,  $R^6$  is hydrogen, each of  $R^7$  and  $R^8$  is methoxy,  $R^9$  is hydrogen, and  $R^{10}$  is methyl, and A is C or N.


**Claim 8** (original): The compound of formula I according to claim 1, wherein each of R<sup>0</sup>, R<sup>1</sup> or R<sup>2</sup> is hydrogen, R<sup>3</sup> is methylsulfamoyl, R<sup>4</sup> is hydrogen, R<sup>5</sup> is bromo, R<sup>6</sup> is hydrogen, each of R<sup>7</sup> and R<sup>8</sup> is hydrogen, and the pair of adjacent substituents R<sup>9</sup> and R<sup>10</sup> is -CH<sub>2</sub>-CH<sub>2</sub>-, and A is C or N.

**Claim 9** (original): The compound of formula 2-{5-Chloro-2-[4-(3-methylamino-pyrrolidin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide.

**Claim 10** (original): A process for the production of a compound of formula I according to claim 1, comprising reacting a compound of formula II



wherein R<sup>0</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are as defined in claim 1; and Y is a leaving group, with a compound of formula III



wherein R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are as defined in claim 1;

and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined in claim 1, into another compound of formula I as defined in claim 1;

and recovering the resulting compound of formula I in free form or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

**Claim 11** (currently amended): A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 9~~claim 1, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

**Claim 12** (canceled)

**Claim 13** (currently amended): A combination comprising a therapeutically effective amount of a compound according to ~~any one of claims 1 to 9~~claim 1 and one or more further drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

**Claim 14** (currently amended): A method for the treatment of neoplastic diseases and immune system disorders in a subject in need thereof which comprises administering an effective amount of a compound according to ~~any one of claims 1 to 9~~claim 1 or a pharmaceutical composition comprising same.

**Claim 15** (currently amended): ~~Use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament~~ A method for the treatment or prevention of a disease which responds to inhibition of focal adhesion kinase or/and IGF-1 Receptor comprising administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

**Claim 16** (currently amended): The use method according to claim 15, wherein the disease to be treated is selected from proliferative disease .

**Claim 17** (currently amended): The use method according to claim 16, wherein the proliferative disease to be treated is selected from a tumor of, breast, renal , prostate, colorectal, thyroid, ovarian, pancreas, neuronal, lung, uterine and gastro-intestinal tumours as well as osteosarcomas and melanomas.

**Claim 18** (currently amended): The use method according to claim 15, wherein the disease to be treated is an immune disease.

**Claim 19** (currently amended): ~~Use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament~~ A method for the treatment or prevention of inflammatory and/or an immune disorder comprising administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof.



**Claim 20** (currently amended): ~~Use~~ The method according to claim 19 wherein the inflammatory and/or immune disorder is selected from transplant rejection, allergy and autoimmune disorders mediated by immune cells including T lymphocytes, B lymphocytes, macrophages, dendritic cells, mast cells and eosinophils.

**Claim 21** (currently amended): The ~~use~~ method according to ~~any one of claims 14 to 49~~claim 14, wherein the compound is 2-[5-Bromo-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide or a pharmaceutically acceptable salt thereof.

**Claim 22** (currently amended): The ~~use~~ method according to ~~any one of claims 14 to 49~~claim 14, wherein the compound is selected from 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, N<sup>2</sup>-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N<sup>4</sup>-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine and 2-[5-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ylamino]-N-isopropyl-benzenesulfonamide, or a pharmaceutically acceptable salt thereof.